Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

•This study was to assess whether three symptomatically defined phenotypes of MDD, (core depression, neurovegetative of melancholia and anxiety), could be differentiated based on acylcarnitine profiles at baseline, after eight weeks of citalopram/escitalopram treatment.•The current data demonstrated...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of affective disorders 2020-03, Vol.264, p.90-97
Hauptverfasser:	Ahmed, Ahmed T., MahmoudianDehkordi, Siamak, Bhattacharyya, Sudeepa, Arnold, Matthias, Liu, Duan, Neavin, Drew, Moseley, M. Arthur, Thompson, J. Will, Williams, Lisa St John, Louie, Gregory, Skime, Michelle K., Wang, Liewei, Riva-Posse, Patricio, McDonald, William M., Bobo, William V., Craighead, W. Edward, Krishnan, Ranga, Weinshilboum, Richard M., Dunlop, Boadie W., Millington, David S., Rush, A. John, Frye, Mark A., Kaddurah-Daouk, Rima
Format:	Artikel
Sprache:	eng
Schlagworte:	Acylcarnitines Antidepressants Carnitine - analogs & derivatives Depression Depressive Disorder, Major - drug therapy Humans Metabolomics P180 Phenotype Phenotypes Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!